Cholinesterase inhibitors are used to treat the symptoms of patients with Alzheimer’s disease, but they have not been shown to reduce the severity of Alzheimer’s disease-related gait disorders. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.